0	7	Nuclear	nuclear	JJ
8	21	transcription	transcription	NN
22	29	factors	factor	NNS
30	34	that	that	WDT
35	39	bind	bind	VBP
40	42	to	to	TO
43	51	elements	element	NNS
52	54	of	of	IN
55	58	the	the	DT
59	63	IL-2	il-2	NN
64	72	promoter	promoter	NN
72	73	.	.	.

74	83	Induction	Induction	NNP
84	96	requirements	requirement	NNS
97	99	in	in	IN
100	107	primary	primary	JJ
108	113	human	human	JJ
114	115	T	t	NN
116	121	cells	cell	NNS
121	122	.	.	.

124	129	Prior	prior	JJ
130	137	studies	study	NNS
138	142	have	have	VBP
143	153	identified	identify	VBN
154	161	several	several	JJ
162	170	elements	element	NNS
171	175	that	that	WDT
176	186	contribute	contribute	VBP
187	189	to	to	TO
190	193	the	the	DT
194	202	activity	activity	NN
203	205	of	of	IN
206	209	the	the	DT
210	214	IL-2	il-2	NN
215	223	promoter	promoter	NN
224	226	in	in	IN
227	230	the	the	DT
231	241	stimulated	stimulate	VBN
242	243	T	t	NN
244	248	cell	cell	NN
249	253	line	line	NN
253	254	,	,	,
255	261	Jurkat	Jurkat	NNP
261	262	.	.	.

263	266	The	the	DT
267	272	sites	site	NNS
273	276	and	and	CC
277	282	their	their	PRP$
283	296	corresponding	correspond	VBG
297	304	nuclear	nuclear	JJ
305	312	binding	binding	NN
313	320	factors	factor	NNS
321	328	include	include	VBP
328	329	:	:	:
330	338	NF-kappa	NF-kappa	NNP
339	340	B	B	NNP
340	341	,	,	,
342	346	AP-1	AP-1	NNP
346	347	,	,	,
348	352	AP-3	AP-3	NNP
352	353	,	,	,
354	359	OCT-1	OCT-1	NNP
359	360	,	,	,
361	364	and	and	CC
365	370	NF-AT	NF-AT	NNP
370	371	.	.	.

372	375	The	the	DT
376	382	latter	latter	JJ
383	384	“	``	``
384	391	nuclear	nuclear	JJ
392	398	factor	factor	NN
399	402	for	for	IN
403	412	activated	activate	VBN
413	414	T	t	NN
415	420	cells	cell	NNS
420	421	”	''	''
422	428	likely	likely	RB
429	440	contributes	contribute	VBZ
441	443	to	to	TO
444	447	the	the	DT
448	454	tissue	tissue	NN
455	466	specificity	specificity	NN
467	469	of	of	IN
470	474	IL-2	il-2	NN
475	479	gene	gene	NN
480	490	expression	expression	NN
490	491	.	.	.

492	497	Using	use	VBG
498	513	electrophoretic	electrophoretic	JJ
514	522	mobility	mobility	NN
523	528	shift	shift	NN
529	535	assays	assay	NNS
535	536	,	,	,
537	539	we	we	PRP
540	544	have	have	VBP
545	552	studied	study	VBN
553	558	these	these	DT
559	572	transcription	transcription	NN
573	580	factors	factor	NNS
581	583	in	in	IN
584	591	primary	primary	JJ
592	593	T	t	NN
594	599	cells	cell	NNS
600	604	from	from	IN
605	610	human	human	JJ
611	616	blood	blood	NN
617	619	to	to	TO
620	626	verify	verify	VB
627	632	their	their	PRP$
633	641	presence	presence	NN
642	644	in	in	IN
645	646	a	a	DT
647	658	physiologic	physiologic	JJ
659	666	setting	setting	NN
667	670	and	and	CC
671	673	to	to	TO
674	682	identify	identify	VB
683	686	the	the	DT
687	694	signals	signal	NNS
695	699	that	that	WDT
700	709	stimulate	stimulate	VBP
710	716	factor	factor	NN
717	725	activity	activity	NN
725	726	.	.	.

727	730	All	all	DT
731	738	factors	factor	NNS
739	742	are	be	VBP
743	750	induced	induce	VBN
751	753	in	in	IN
754	757	the	the	DT
758	764	nuclei	nucleus	NNS
765	767	of	of	IN
768	769	T	t	NN
770	775	cells	cell	NNS
776	780	upon	upon	IN
781	791	activation	activation	NN
792	796	with	with	IN
797	805	mitogens	mitogen	NNS
806	809	but	but	CC
810	813	not	not	RB
814	818	with	with	IN
819	828	exogenous	exogenous	JJ
829	833	IL-2	il-2	NN
834	840	growth	growth	NN
841	847	factor	factor	NN
847	848	.	.	.

849	856	However	however	RB
856	857	,	,	,
858	861	the	the	DT
862	871	signaling	signaling	NN
872	884	requirements	requirement	NNS
885	888	and	and	CC
889	900	sensitivity	sensitivity	NN
901	903	to	to	TO
904	911	protein	protein	NN
912	921	synthesis	synthesis	NN
922	932	inhibitors	inhibitor	NNS
933	939	differ	differ	VBP
940	952	considerably	considerably	RB
952	953	.	.	.

954	958	Only	only	RB
959	962	the	the	DT
963	973	activities	activity	NNS
974	977	for	for	IN
978	983	NF-AT	NF-AT	NNP
984	987	and	and	CC
988	992	AP-1	ap-1	NN
993	998	sites	site	NNS
999	1006	require	require	VBP
1007	1010	two	two	CD
1011	1018	signals	signal	NNS
1019	1022	for	for	IN
1023	1030	optimal	optimal	JJ
1031	1040	induction	induction	NN
1040	1041	,	,	,
1042	1046	i.e.	i.e.	FW
1046	1047	,	,	,
1048	1051	PMA	PMA	NNP
1052	1056	plus	plus	CC
1057	1063	either	either	CC
1064	1070	lectin	lectin	NN
1071	1073	or	or	CC
1074	1082	antibody	antibody	NN
1083	1085	to	to	TO
1086	1089	the	the	DT
1090	1093	CD3	cd3	NN
1094	1096	or	or	CC
1097	1101	CD28	cd28	NN
1102	1109	surface	surface	NN
1110	1119	molecules	molecule	NNS
1119	1120	.	.	.

1121	1126	Other	other	JJ
1127	1134	factors	factor	NNS
1135	1138	are	be	VBP
1139	1146	induced	induce	VBN
1147	1149	by	by	IN
1150	1156	lectin	lectin	NN
1156	1157	,	,	,
1158	1166	antibody	antibody	NN
1166	1167	,	,	,
1168	1174	and/or	and/or	CC
1175	1178	PMA	PMA	NNP
1179	1184	alone	alone	RB
1184	1185	.	.	.

1186	1191	After	after	IN
1192	1203	appropriate	appropriate	JJ
1204	1215	stimulation	stimulation	NN
1215	1216	,	,	,
1217	1221	both	both	CC
1222	1227	NF-AT	NF-AT	NNP
1228	1231	and	and	CC
1232	1236	AP-1	AP-1	NNP
1237	1240	are	be	VBP
1241	1251	peculiarly	peculiarly	RB
1252	1261	sensitive	sensitive	JJ
1262	1264	to	to	TO
1265	1268	the	the	DT
1269	1276	protein	protein	NN
1277	1286	synthesis	synthesis	NN
1287	1296	inhibitor	inhibitor	NN
1297	1307	anisomycin	anisomycin	NN
1307	1308	.	.	.

1309	1312	Our	our	PRP$
1313	1317	data	datum	NNS
1318	1327	correlate	correlate	VBP
1328	1331	the	the	DT
1332	1340	activity	activity	NN
1341	1343	of	of	IN
1344	1349	NF-AT	NF-AT	NNP
1350	1353	and	and	CC
1354	1358	AP-1	ap-1	NN
1359	1361	in	in	IN
1362	1365	gel	gel	NN
1366	1371	shift	shift	NN
1372	1378	assays	assay	NNS
1379	1383	with	with	IN
1384	1387	the	the	DT
1388	1391	two	two	CD
1392	1399	signals	signal	NNS
1400	1412	requirements	requirement	NNS
1413	1416	for	for	IN
1417	1421	IL-2	il-2	NN
1422	1426	gene	gene	NN
1427	1437	expression	expression	NN
1437	1438	.	.	.